Lex Machina First Annual Product Liability Litigation Report
Lex Machina First Annual Product Liability Litigation Report
Good news from our friends at Lex Machina, particularly if you’re interested or involved in product liability litigation. Lex Machina just released its First Annual Product Liability Litigation Report. This article presents some highlights from that report, as well as the official press release from the company.“Lex Machina’s Inaugural Product Liability Litigation Report Focuses on Burgeoning Medical Device and Pharmaceutical Product Case FilingsLex Machina, a LexisNexis company and creator of the award-winning Legal Analytics® platform, released findings from its first annual Product Liability Litigation report [yesterday, April 2]. The report contains data on more than 400,000 product liability cases pending in U.S. District Courts from January 1, 2009 to Dec 31, 2017 – including multi-district litigation (MDL) and non-MDL cases, with special emphasis on medical devices and pharmaceutical products.The Product Liability Litigation report showcases data and trends surrounding cases in which a party seeks compensation for physical or emotional injury, or property damage, caused by a defect in a product. The report spotlights the large numbers of claims related to pharmaceuticals and medical devices. The report includes detailed insights on case findings, resolutions timing, damages awarded in verdicts, and approved class action settlements, giving attorneys a better understanding of potential outcomes, so they can provide better client counsel.‘Every year, the number of product liability cases filed in District Court consistently outpaces the combined case filings for patent, commercial, employment, trademark, copyright, antitrust, securities, and bankruptcy appeals,’ said Owen Byrd, General Counsel and Chief Evangelist at Lex Machina. ‘Of those product liability cases, medical device and pharmaceutical litigation accounts for the lion’s share of all filings, which is why we’ve chosen to feature this sector in our first annual report.’MDL-associated cases comprised more than 97% of medical device/pharmaceutical cases filed in 2017, with only 667 of the 29,185 total cases not affiliated with an MDL master case. Lex Machina provides tools to enable users to either exclude or include MDL-associated cases, depending on what case set will yield the most meaningful insights to the user.
Product Liability by Nick Youngson, CC BY-SA 3.0, Alpha Stock Images, no changes.
Since January 1, 2009, more than 289,200 product liability cases were filed in District Court, involving products classified by Lex Machina as medical devices or pharmaceuticals, including MDL-associated cases. The next largest categories was asbestos, with more than 87,300 cases. Asbestos case filings in District Court have declined from tens of thousands per year during 2009-2011 to merely hundreds per year during 2012-2016.
Almost all (96%) product liability cases involving medical devices or pharmaceutical products are settled or resolved procedurally, instead of on the merits of the case. When product liability cases are decided on the merits, defendants prevail about 90% of the time.
Cases litigated through to court award of damages are rare in product liability cases involving medical devices and pharmaceutical products.
Three districts tied for the largest percent of non-MDL filings across all product categories from 2009 to 2017: Central District of California (C.D. Cal), Eastern District of Pennsylvania and District of New Jersey – each with 5%.
Since 2009, New Jersey has had the most non-MDL-associated medical device/pharmaceutical case filings (8%). C.D. Cal and Eastern District of Louisiana are tied at 6%, and Northern District of Texas captured 5%. This data includes cases that may later become associated with an MDL.
In 2016, however, the Eastern District of Louisiana captured 14% of medical device/pharmaceutical case filings cases, beating New Jersey (13%) and the District of New Hampshire (9%).
About Press Release
This post is an authorized copy of a press release and was not written by LegalReader.